Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 10th Preview)
-
FDA leadership stability
The FDA moved to lock in continuity for drug and biologics regulation by naming Michael Davis permanent director of CDER and Karim Mikhail permanent director of CBER. Acting designations were removed as the agency works through a leadership transition ahead of an unscheduled commissioner confirmation process. The move follows a period of director turnover that unsettled investors and industry stakeholders. Analysts framed the appointments as a signal that major policy swings are less likely, with Davis and Mikhail emphasizing a return to normal operations. Separately, the FDA created a new deputy commissioner role for technology and artificial intelligence, with Jared Seehafer appointed to that position, underscoring the agency’s intent to integrate AI into review workflows.
-
Clinical setbacks and competitive pressure in oncology
Novartis disclosed two separate Phase III failures that further stress its late-stage pipeline. The company said delpacibart etedesiran failed to meet the primary endpoint in the HARBOR trial for myotonic dystrophy type 1, and pelacarsen also missed its Phase III cardiovascular outcomes target in the Lp(a)HORIZON study for patients with elevated lipoprotein(a). Analysts highlighted that the clinical misses weaken confidence in Lp(a)-lowering as a standalone strategy, despite strong biomarker reductions in earlier work. The denials also come amid other setbacks that have recently led to study suspensions and strategic review. Across the portfolio, investors are now focusing on whether Novartis can isolate patient subgroups or adjust endpoints to recover risk tolerance going into later-stage reads.
-
Breast cancer regulatory win for a next-gen SERD
AstraZeneca won an FDA accelerated approval for camizestrant, trading under the Etcamah brand, after an advisory committee previously voted against the drug’s first-line breast cancer use. The approval supports HR+/HER2− advanced breast cancer with detected ESR1 mutations during aromatase inhibitor and CDK4/6 inhibitor therapy. The decision also includes Guardant Health’s Guardant360 companion diagnostic to identify ESR1 mutations, enabling earlier treatment switches than prior standards that typically required radiographic progression. With the FDA rejecting the broader paradigm question earlier in the year, the approval underscores regulators’ willingness to accept progression-free survival signals in narrowly defined biomarker-positive populations.
-
CAR-T efficacy signal in relapsed/refractory myeloma
Bristol Myers Squibb reported Phase 2 success for an engineered GPRC5D-directed CAR-T program, highlighting a potential new option for patients after relapse when standard approaches fall short. The company framed results as a step toward a more distinct treatment setting in multiple myeloma, a disease where sequencing and prior exposure increasingly determine outcomes. The report comes as the myeloma CAR-T landscape is crowded with multiple BCMA-directed and next-generation targets, increasing the importance of target biology and patient stratification. Analysts will likely focus on response depth, durability, and safety signals in the broader datasets. Investors are also watching how BMS positions this construct relative to competing therapies with different eligibility thresholds and time-to-treatment constraints.
-
RNAi and obesity funding rounds
Moonwalk Biosciences raised $70 million in a Series B to move MW101, an adipose-targeted RNAi obesity candidate, toward first-in-human trials planned for late 2027. The funding supports IND-enabling studies and the advancement of additional siRNA programs focused on distinct adipose mechanisms including lipolysis, adipogenesis, thermogenesis and energy homeostasis. The company’s approach aims to reduce fat without the muscle loss and appetite effects that can accompany incretin-based therapies, with preclinical data describing weight and fat mass reductions in animals while maintaining lean mass. The financing also reflects continued investor appetite for non-incretin metabolic modalities, especially those with tissue-selective delivery intended to improve durability and adherence profiles.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.